» Articles » PMID: 39161161

Fecal Microbiota from Patients with Parkinson's Disease Intensifies Inflammation and Neurodegeneration in A53T Mice

Overview
Specialties Neurology
Pharmacology
Date 2024 Aug 20
PMID 39161161
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: We evaluated the potential of Parkinson's disease (PD) fecal microbiota transplantation to initiate or exacerbate PD pathologies and investigated the underlying mechanisms.

Methods: We transplanted the fecal microbiota from PD patients into mice by oral gavage and assessed the motor and intestinal functions, as well as the inflammatory and pathological changes in the colon and brain. Furthermore, 16S rRNA gene sequencing combined with metabolomics analysis was conducted to assess the impacts of fecal delivery on the fecal microbiota and metabolism in recipient mice.

Results: The fecal microbiota from PD patients increased intestinal inflammation, deteriorated intestinal barrier function, intensified microglia and astrocyte activation, abnormal deposition of α-Synuclein, and dopaminergic neuronal loss in the brains of A53T mice. A mechanistic study revealed that the fecal microbiota of PD patients stimulated the TLR4/NF-κB/NLRP3 pathway in both the brain and colon. Additionally, multiomics analysis found that transplantation of fecal microbiota from PD patients not only altered the composition of the gut microbiota but also influenced the fecal metabolic profile of the recipient mice.

Conclusion: The fecal microbiota from PD patients intensifies inflammation and neurodegeneration in A53T mice. Our findings demonstrate that imbalance and dysfunction in the gut microbiome play significant roles in the development and advancement of PD.

Citing Articles

Fecal microbiota from patients with Parkinson's disease intensifies inflammation and neurodegeneration in A53T mice.

Yang H, Shao Y, Hu Y, Qian J, Wang P, Tian L CNS Neurosci Ther. 2024; 30(8):e70003.

PMID: 39161161 PMC: 11333719. DOI: 10.1111/cns.70003.

References
1.
Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rub U . Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol. 2003; 249 Suppl 3:III/1-5. DOI: 10.1007/s00415-002-1301-4. View

2.
Shao Y, Li T, Liu Z, Wang X, Xu X, Li S . Comprehensive metabolic profiling of Parkinson's disease by liquid chromatography-mass spectrometry. Mol Neurodegener. 2021; 16(1):4. PMC: 7825156. DOI: 10.1186/s13024-021-00425-8. View

3.
Shannon K, Keshavarzian A, Dodiya H, Jakate S, Kordower J . Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases. Mov Disord. 2012; 27(6):716-9. DOI: 10.1002/mds.25020. View

4.
Kumar M, Sandhir R . Hydrogen sulfide suppresses homocysteine-induced glial activation and inflammatory response. Nitric Oxide. 2019; 90:15-28. DOI: 10.1016/j.niox.2019.05.008. View

5.
DuPont H, Suescun J, Jiang Z, Brown E, Essigmann H, Alexander A . Fecal microbiota transplantation in Parkinson's disease-A randomized repeat-dose, placebo-controlled clinical pilot study. Front Neurol. 2023; 14:1104759. PMC: 10019775. DOI: 10.3389/fneur.2023.1104759. View